Sangamo Joins Companies Halting Sickle Cell Gene|edited Cell ...

Sangamo Joins Companies Halting Sickle Cell Gene-edited Cell ...

Sangamo Joins Companies Halting Sickle Cell Gene-edited Cell Therapy Programs ... The company has halted phase 3 plans for BIVV003 in favor of ...

Sangamo, joining other rivals, shelves sickle cell therapy

Sangamo Therapeutics is shelving later-stage development of its sickle cell drug, joining two other biotechs that, in the last 24 hours, have been forced to ...

Sangamo Announces Transition of SAR445136 Sickle Cell Disease ...

6, 2022-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that Sanofi will be transitioning its rights ...

Sickle cell pipeline narrows as gene therapy developers rethink ...

Graphite Bio and Sangamo are stopping work on their respective gene therapies, while Intellia revealed partner Novartis has ended ...

Sangamo Searching for Options After Sanofi Withdraws from SCD ...

SAR445136 is a zinc finger nuclease gene-edited cell therapy being developed for sickle cell disease (SCD). The rights return to Sangamo by the ...

Sangamo's sickle cell alliance with Sanofi grinds to a halt as pharma ...

The Paris-based pharma giant will be returning its rights and obligations on SAR445136, a zinc finger nuclease gene-edited cell therapy back to ...

Clinical trial: Sickle Cell Disease, SCD, (NCT03653247)

(06-03-2023) Sangamo Joins Companies Halting Sickle Cell Gene-edited Cell Therapy Programs. (12-12-2021) Sangamo Therapeutics Announces Updated Preliminary ...

Investors & Media - Sangamo Therapeutics, Inc.

Presented promising data from the Phase 1/2 PRECIZN-1 study of BIVV003, a zinc finger nuclease gene-edited cell therapy candidate for the ...

Sangamo lays off 27% of US staff in latest refocus - Fierce Biotech

The significant reduction in head count is equivalent to 27% of the company's U.S. workforce. The shrunken business will focus on Sangamo's ...

Sangamo and Pfizer announce collaboration for development of ...

Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, ALS and FTLD, ...

CGTLive's Weekly Rewind – March 10, 2023 - CGTLive®

1. Sangamo Joins Companies Halting Sickle Cell Gene-edited Cell Therapy Programs ... The company halted its phase 3 plans for BIVV003 in favor of therapies for ...

SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE ...

(NYSE: PFE) today announced an exclusive, global collaboration and license agreement for the development and commercialization of gene therapy ...

Genome editing coming of age for hemoglobinopathy - PMC

Instead of elevating HbF, Graphite Bio directly corrected the sickle mutation in the HBB gene, using HiFi Cas9 to induce a double-strand DNA break followed by ...

Sanofi Hands Sickle Cell Disease Program Back to Sangamo

Sangamo Therapeutics reported that Sanofi is terminating their collaboration related to SAR445136, a zinc finger nuclease gene-edited cell ...

Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo ... - Scrip

Sanofi's decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy. ... Source: Alamy Sanofi's decision ...

Sickle Cell Disease - Treatment | NHLBI, NIH

In December 2023, the U.S. Food and Drug Administration approved two new gene therapies that are transformative therapies for sickle cell ...

Sangamo Therapeutics - Wikipedia

Sangamo Therapeutics, Inc is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and ...

Sangamo Announces FDA Clearance Of Investigational New Drug ...

Sangamo has a strategic collaboration with Bioverativ, Inc. for hemoglobinopathies, including sickle cell disease and beta-thalassemia, and with ...

Clinical genome editing to treat sickle cell disease—A brief update

In 2019, Sangamo Therapeutics started a phase I/II clinical trial (NCT03653247) for eight SCD patients to assess the safety and efficacy of BIVV003, ex vivo ...

CRISPR Clinical Trials: A 2024 Update - Innovative Genomics Institute

In late 2023, we saw the first-ever approval of CRISPR-based medicine: Casgevy, a cure for sickle cell disease (SCD) and transfusion-dependent beta thalassemia ...